Theasinensin C 是一种口服有效的肾素抑制剂和菌群调节剂,对肾素活性的 IC50 为 40.21 μM,可在肠道菌群中选择性富集嗜黏蛋白阿克曼菌 (Akkermansia muciniphila)、增强其介导的黏蛋白 PTS 结构域水解、驱动管腔谷氨酰胺与丝氨酸积累,并调控肠-肾-肝谷氨酰胺/丝氨酸代谢信号通路以促进肌酸生物合成,从而改善认知功能、减少促炎细胞因子、缓解神经病理改变并恢复肠道屏障完整性,可用于高血压及高果糖饮食诱导的神经炎症相关研究。
产品编号: MS-Y25327 CAS No.: 89013-69-4 分子式: C30H26O14 分子量: 610.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

Theasinensin C 是一种口服有效的肾素抑制剂和菌群调节剂,对肾素活性的 IC50 为 40.21 μM,可在肠道菌群中选择性富集嗜黏蛋白阿克曼菌 (Akkermansia muciniphila)、增强其介导的黏蛋白 PTS 结构域水解、驱动管腔谷氨酰胺与丝氨酸积累,并调控肠-肾-肝谷氨酰胺/丝氨酸代谢信号通路以促进肌酸生物合成,从而改善认知功能、减少促炎细胞因子、缓解神经病理改变并恢复肠道屏障完整性,可用于高血压及高果糖饮食诱导的神经炎症相关研究。

生物实验数据

生物活性 Theasinensin C is an orally effective renin inhibitor and microbiota modulator with an IC50 of 40.21 μM against renin activity that selectively enriches Akkermansia muciniphila in the gut microbiota, enhances its mediated hydrolysis of the mucin PTS domain, drives luminal glutamine and serine accumulation, and regulates the gut-kidney-liver glutamine/serine metabolic signaling pathway to promote creatine biosynthesis, thereby improving cognitive function, reducing pro-inflammatory cytokines, alleviating neuropathological changes, and restoring intestinal barrier integrity, and can be used for research on hypertension and high-fructose diet-induced neuroinflammation.
体外研究
(In Vitro)

Theasinensin C (48 h) 可增强 Akkermansia muciniphila XJ 240720 介导的黏蛋白 PTS 结构域降解,使管腔 L-谷氨酰胺和 L-丝氨酸水平显著升高。

体内研究
(In Vivo)

Theasinensin C (150 mg/kg;灌胃;每日;持续 8 周) 可通过改善认知功能、降低全身及中枢炎症标志物水平、恢复肠道屏障完整性,以及重构肠道菌群以富集 Akkermansia muciniphila 等有益菌,缓解雄性 C57BL/6J 小鼠中由 HFrD 诱导的神经炎症。
Theasinensin C (150 mg/kg;灌胃;每日给药;持续 8 周) 可减轻高脂饮食 (HFrD) 诱导的经抗生素预处理的无菌雄性 C57BL/6J 小鼠神经炎症,改善认知功能并降低中枢炎症标志物水平;且与 Akkermansia muciniphila 来源的代谢物联合使用时,其疗效会增强。

Animal Model: C57BL/6J (8-week-old male, SPF grade, HFrD-induced neuroinflammation)
Dosage: 150 mg/kg/day
Administration: oral gavage; daily; 8 weeks
Result: Shortened escape latency in MWM training, increased percentage of distance and time spent in the target quadrant, and increased number of platform crossings compared to HFrD controls.
Decreased serum levels of LPS, TNF-α, and IL-6, and increased serum IL-10 levels compared to HFrD controls.
Reduced number of damaged neurons in the hippocampus and cortex; decreased mean fluorescence density of GFAP and IBA-1 in the hippocampus; downregulated hippocampal and cortical mRNA expression of Il-6, Tnf-α, Il-1β, Mcp-1, iNos, and Cox-2 compared to HFrD controls.
Alleviated colonic shortening, submucosal edema, inflammatory infiltration, crypt damage, and goblet cell loss; downregulated colonic mRNA expression of Tnf-α, Il-6, Il-1β, and Mcp-1; upregulated colonic mRNA expression of Zo-1, Occludin, Claudin-1, and Muc1 compared to HFrD controls.
Selectively enriched beneficial taxa; suppressed pro-inflammatory taxa including Desulfovibrio desulfuricans, Neisseria mucosa, Helicobacter hepaticus, and Ruminococcus gnavus compared to HFrD controls; restored HFrD-reduced levels of acetate, propionate, i-butyrate, n-butyrate, n-valerate, lactic acid, and total acids in colonic contents, and upregulated intestinal SCFA receptor genes Ffar2 and Ffar3.
Animal Model: C57BL/6J (8-week-old male, SPF grade, antibiotic-pretreated germ-free, HFrD-induced neuroinflammation)
Dosage: 150 mg/kg/day
Administration: oral gavage; daily; 8 weeks
Result: Reduced escape latency in MWM training, increased percentage of distance and time spent in the target quadrant, and increased number of platform crossings compared to HFrD controls (efficacy was less than the combined metabolite group of theasinensin C and Akkermansia muciniphila, but greater than HFrD controls).
Reduced number of damaged neurons in the hippocampus and cortex; decreased mean fluorescence density of GFAP and IBA-1 in the hippocampus; downregulated hippocampal and cortical mRNA expression of Il-6, Tnf-α, Il-1β, Mcp-1, iNos, and Cox-2 compared to HFrD controls.
性状 固体
颜色 Off-white to light brown

化学信息

分子量 610.52
分子式 C30H26O14
CAS No. 89013-69-4

储存&溶解度

储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础